Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease
Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of natalizumab in
adolescents (ages 12-17) diagnosed with moderately to severely active Crohn's disease (CD).
It is thought that natalizumab may stop the movement of certain cells, known as white blood
cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the
symptoms of Crohn's disease.
Patients who complete this study may be eligible for long-term natalizumab therapy via
extension protocol ELN100226-352.